The Impact of IGF-I Gene Polymorphisms on Coronary Artery Disease Susceptibility

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 2, 2013, Pages 162-169

  Lin, Hsiu Ling ^a,b   Ueng, Kwo Chang ^a,b   Wang, Hsiang Ling ^c   Chen, Tsung Po ^a   Yang, Shun Fa ^a   Chu, Shu Chen ^d   Hsieh, Yih Shou ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAICHUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Coronary artery disease; IGF I; IGFBP 3; Single nucleotide polymorphism

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TAIWAN;

AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS, NONPARAMETRIC; TAIWAN;

EID: 84875620997     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21581     Document Type: Article

References (67)

1. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004;24:435-444.
2. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem 1990;190:445-462.
3. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
4. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007;28:20-47.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
6. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998;140:19-24.
7. Burchardt P, Gozdzicka-Jozefiak A, Siminiak T. IGF-1-A new risk factor for coronary atherosclerosis. Kardiol Pol 2006;64:1297-1302.
8. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-244.
9. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011;7:11-24.
10. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004;363:1346-1353.
11. Bubley GJ, Balk SP, Regan MM, et al. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. Urol 2002;168:2249-2252.
12. Moller DE, Flier JS. Insulin resistance-Mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-948.
13. Burchardt P, Gozdzicka-Jozefiak A, Zurawski J, et al. Are elevated levels of IGF-1 caused by coronary arteriesoclerosis? Molecular and clinical analysis. Protein J 2010;29:538-544
14. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int J Cancer 2009;124:2416-2429.
15. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58:124-145.
16. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-471.
17. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995;6:164-179.
18. Richard E. Weitzman Memorial Award of the Endocrine Society to Mitchell Avery Lazar. Endocr Rev 1995;16:557-558.
19. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): The multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2004;13:1444-1451.
20. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: Results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010;126:1702-1715.
21. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: A systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2-19.
22. Markussis V, Beshyah SA, Fisher C. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992;340:1188-1192.
23. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996;77:200-202.
24. Goodman-Gruen D, Barrett-Connor E, Rosen C. IGF-1 and ischemic heart disease in older people. J Am Geriatr Soc 2000;48:860-861.
25. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: Relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998;18:277-282.
26. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: A population-based case-control study. Circulation 2002;106:939-944.
27. Abe N, Matsunaga T, Kameda K, et al. Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfunction and advanced heart failure. J Am Coll Cardiol 2006;48:1387-1395.
28. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005;90:5937-5941.
29. Janssen JA, Lamberts SW. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-477.
30. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003;157:25-31.
31. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-637.
32. Boger RH, Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease. Circulation 2003;107:e193.
33. Schuler-Luttmann S, Monnig G, Enbergs A, et al. Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol 2000;20:E10-E15.
34. Weng CJ, Hsieh YH, Tsai CM, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010;17:1808-1815.
35. Yoon AJ, Zavras AI, Chen MK, Lin CW, Yang SF. Association between Gly1619ARG polymorphism of IGF2R domain 11 (rs629849) and advanced stage of oral cancer. Med Oncol 2012;29:682-685.
36. Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst 2006;98:123-134.
37. Hoyo C, Grubber J, Demark-Wahnefried W, et al. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc 2007;99:718-722.
38. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-1280.
39. Han S, Peng J, Zhang R, et al. Lack of association of GH T1663A variation and IGFBP3-202A/C polymorphism with risk of ischemic stroke in Chinese. Clin Chem Lab Med 2008;46:1056-1058.
40. WHO publishes definitive atlas on global heart disease and stroke epidemic. Indian J Med Sci 2004;58:405-406.
41. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004;110:2260-2205.
42. Heald AH, Golding C, Sharma R, et al. A substitution model of dietary manipulation is an effective means of optimising lipid profile, reducing C-reactive protein and increasing insulin-like growth factor-1. Br J Nutr 2004;92:809-818.
43. Conti E, Musumeci MB, De Giusti M, et al. IGF-1 and atherothrombosis: Relevance to pathophysiology and therapy. Clin Sci (Lond) 2011;120:377-402.
44. Lam CS, Chen MH, Lacey SM, et al. Circulating insulin-like growth factor-1 and its binding protein-3: Metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol 2010;30:1479-1484.
45. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Kelly J, Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol 2010;30:1916-1924.
46. Fernandez-Hernando C, Ackah E, Yu J, et al. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 2007;6:446-457.
47. Fernandez-Hernando C, Jozsef L, Jenkins D, Di Lorenzo A, Sessa WC. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:2033-2040.
48. Wickman A, Jonsdottir IH, Bergstrom G, Hedin L. GH and IGF-I regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. Eur J Endocrinol 2002;147:523-533.
49. Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999;22:82-88.
50. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005;111:2981-2987.
51. Taylor WR, Alexander RW. Autocrine control of wound repair by insulin-like growth factor I in cultured endothelial cells. Am J Physiol 1993;265:C801-C805.
52. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-2615.
53. Kao PC, Matheny AP, Jr., Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994;78:310-312.
54. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 1994;41:85-93.
55. Norat T, Dossus L, Rinaldi S, et al. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr 2007;61:91-98.
56. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852-861.
57. Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev 2001;10:443-452.
58. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: Functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-642.
59. Yazdanpanah M, Rietveld I, Janssen JA, et al. An insulin-like growth factor-I promoter polymorphism is associated with increased mortality in subjects with myocardial infarction in an elderly Caucasian population. Am J Cardiol 2006;97:1274-1276.
60. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW. A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 2003;148:171-175.
61. Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men's health study. Prostate 2008;68:296-305.
62. Al-Zahrani A, Sandhu MS, Luben RN, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006;15:1-10.
63. Su X, Colditz GA, Willett WC, et al. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer 2010;126:180-190.
64. Hicks AA, Pramstaller PP, Johansson A, et al. Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet 2009;5:e1000672.
65. Mong JL, Ng MC, Guldan GS, et al. Associations of insulin-like growth factor binding protein-3 gene polymorphisms with IGF-I activity and lipid parameters in adolescents. Int J Obes (Lond) 2009;33:1446-53.
66. Li L, Huang X, Huo K. IGFBP3 polymorphisms and risk of cancer: A meta-analysis. Mol Biol Rep 2010;37:127-140.
67. Safarinejad MR. Insulin-like growth factor binding protein-3 (IGFBP-3) gene variants are associated with renal cell carcinoma. BJU Int 2011;108:762-770.